Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
November 7, 2024
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Krystal, and hello to everyone this afternoon. We appreciate you being with us today. Joining us are our President and Chief Executive Officer, Howard Robin; our Chief Research and Development Officer, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; and our Chief Financial Officer, Sandra Gardiner. During this call, we anticipate offering forward-looking statements about our business, including ones concerning the therapeutic potential of and future development plans for drug candidates and research programs; when clinical studies will start and when clinical data for drug candidates will become available; the timing of and plans for upcoming clinical data presentations; the formation, future development plans, or success of our collaboration agreements; financial guidance; and certain other statements about the future of the business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of those lie beyond our control. Our actual results could differ materially from these statements. Key risks and uncertainties appear in our Form 10-Q filed on August 9th, 2024, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThank you, Vivian, and thanks to everyone for being here today. In Q3, we achieved meaningful momentum in moving forward our extremely promising pipeline, which is centered on immunology and inflammation. A key point is that we remain intensely dedicated to pushing ahead with the Phase 2 trials for our lead aspect. Our lead asset, rezpegaldesleukin, referred to as REZPEG, is engineered to directly grow functional Treg cells and interact with several immunoregulatory pathways in individuals suffering from autoimmune disorders. As everyone is aware, REZPEG has produced encouraging early results that back its capacity to emerge as a highly differentiated and novel mechanism for treating ectopic dermatitis and alopecia. Roughly 15 million individuals currently live with moderate to severe ectopic dermatitis in the USA. Estimates suggest that fewer than 10% of the patients who might qualify for biologics are in fact getting therapy. We think novel mechanisms are essential for expanding this underserved biologic sector. That's why REZPEG's promise as a first in class T regulatory cell mechanism for these patients facing serious unmet need excites us so much. Enrollment in our Phase 2 trial for ectopic dermatitis is proceeding as planned, with top line data expected in the first half of 2025; we're quite happy with how quickly patients are enrolling in this sizable 400-patient Phase 2b trial, and JZ will provide additional details on the ongoing study shortly. We also see considerable promise for REZPEG in assisting those with alopecia areata. Almost 7 million individuals within the United States by itself have or will get the condition. This disorder heavily impacts patients' quality of life, and the JAK inhibitor therapies available now lack durability, come with high relapse rates, and pose major safety concerns. So there's a pressing unmet medical need for fresh therapies for these individuals too. Enrollment in our second Phase 2b trial of REZPEG involving 86 patients with severe to very severe alopecia areata is likewise on schedule for top line data in the second half of 2025. A couple of weeks back, we released in Nature Communications the findings from the Phase 1b trial of REZPEG in ectopic dermatitis and psoriasis; when viewed together, these results reinforce our choice to move forward with the clinical strategy and progress our Two phase 2b trials in ectopic dermatitis and alopecia areata, and JZ will elaborate on the key data from these publications afterward during the call. Shifting to our preclinical efforts. We keep moving NKTR-165 forward, our innovative TNFR2 agonist antibody program. Because TNF receptor 2 matters so much, NKTR-165 might eventually turn into a first in class therapy for autoimmune conditions like multiple sclerosis, ulcerative colitis, and vitiligo. Previously this year at EULAR, we shared the initial preclinical results for this program, demonstrating that NKTR-165 showed selective improvement of Treg cell function, and JZ will go into more detail on that afterward. Right now we're performing IND enabling studies, aiming to get ready for an IND submission in the second half of 2025. So, taking what we learned from NKTR-165, we've built a pipeline of bispecific molecules that contain TNFR2, combining TNFR2 agonism with other antibody targets, and we're eager to share further detail on that pipeline as development candidates come forward. Beyond NKTR-165, there's also our PEG CFS1 program, NKTR-422, sitting in the preclinical stage, which was designed to selectively modulate the resolution processes involved in inflammation. We're happy to report that preclinical data across multiple animal models, collagen induced arthritis among them, was chosen for an oral presentation at the 2024 ACR Convergence meeting, which takes place in Washington, DC. This marks the first time we'll present preclinical data from this program, and NKTR-422 could potentially be applied across a range of therapeutic indications, covering both acute and chronic inflammation. Moving on, I'd like to talk about NKTR-255, our oncology IL15 program. We recently put out several data sets from this program, published in blood and at ASH. What these data demonstrate is that NKTR-255 is capable of enhancing CAR-T therapy activity. Today we delivered a late breaking abstract at SITC showing NKTR-255 used in a new application; in that abstract, NKTR-255 demonstrated it could recover radiation induced lymphopenia among patients with non-small cell lung cancer, and Mary will go into more detail on that program during today's call. Now, before handing things over to JZ, I want to touch briefly on the transaction we announced this week. Earlier this week, we shared that an agreement has been signed to sell our commercial PEGylation reagent manufacturing facility located in Huntsville to Ampersand Capital Partners. The PEG reagent facility is going to be spun out as a standalone portfolio company of Ampersand. Nektar stands to receive $90 million in total compensation, made up of $70 million in cash plus $20 million in equity ownership in that new portfolio company, and the deal should close on December 2nd; besides continuing to serve the plant's current customers, this new company will keep meeting Nektar's PEG supply requirements for REZPEG along with our other PEG related pipeline programs. We'll hold onto all rights to royalties and milestones under the existing PEG license agreements, including the ones tied to DAPI pegol, which has already shown positive Phase 3 efficacy in lupus; this strategic divestiture of the plant lets us streamline operations and further strengthens Nektar's financial position as we approach top line data readouts in 2025. The proceeds will push our cash runway out into the fourth quarter of 2026. With that, I'll turn the call over to JZ for an R&D discussion. JZ?
Jonathan Zalevsky
executiveThanks, Howard. Let's begin with REZPEG. Among the therapies being developed in this space, it represents the most sophisticated IL2 Treg mechanism out there. We see significant potential for it in two conditions: atopic dermatitis and alopecia areata. From our Phase 1b trial of REZPEG in atopic dermatitis, the data showed efficacy that scaled with dose, along with durability that was encouraging and persisted well beyond the point when patients finished the 12-week induction period. In fact, whether we looked at outcomes reported by patients or endpoints assessed by physicians, the patterns we saw were identical: effect appearing quickly, dependence on dose, and control lasting a long time. The speed at which it works and the extended disease control that continues after dosing stops compare favorably to — indeed, outshine — dupilumab or JAK inhibitors. These promising results have made both us and physicians quite enthusiastic about the possibility of long-lasting responses and maintenance dosing that isn't needed often with REZPEG in atopic dermatitis. As Howard noted, we published preclinical and clinical data on REZPEG last month in Nature Communication. Results from mouse models plus two human Phase 1b studies — one in atopic dermatitis, one in psoriasis — are included in the manuscript, and together they show REZPEG's potential for treating inflammatory skin diseases. The clinical findings from these two distinct inflammatory skin conditions demonstrated that REZPEG led to improvements in physician assessed disease activity as well as patient reported outcomes. These encouraging results clinically validate the Treg hypothesis — that causally restoring Treg function via a central pathway of IL2 receptor driven Treg Rescue may carry therapeutic potential across a range of chronic skin diseases. They also show that REZPEG can affect multiple pathways that drive disease and is uniquely positioned to tackle a diversity of immunopathology. On top of that, a consistent safety and tolerability profile emerged across the studies, matching previously published data. The exciting cross indication clinical efficacy we saw is supported by serum biomarker analysis, which shows REZPEG can modulate multiple immunoregulatory pathways to deliver rapid onset and duration of efficacy. In the atopic dermatitis study, we incorporated longitudinal serum proteomics analysis, and it revealed the plural virality of Treg mediated pathways with possible effects on the tissue resident memory T-cell population, producing sustained efficacy as seen in the antigen challenged mouse models and in the clinical trial. These proteomic findings lend further validation to our therapeutic approach — using a Treg stimulator to dampen inflammatory responses while simultaneously restoring immune balance in patients with chronic inflammatory skin diseases. Taking everything together, including the biomarker analysis, we now understand how treatment with REZPEG produced dose dependent efficacy in the Phase 1b study over the 12-week treatment period, including its rapid onset of action, and we also gain insight into pathways that could account for the sustained efficacy observed in the study even after treatment was removed. All of this supports the design of our ongoing Phase 2b study in atopic dermatitis, which is enrolling roughly 400 patients with moderate to severe disease across three different regimens of REZPEG versus placebo evaluated over a 16-week induction period. Once patients get through the induction phase and hit the criteria needed to move on to maintenance, they'll undergo rerandomization into one of two maintenance dosing schedules, staying at the same dose level they started with, and receive that dose either monthly or every three months. The maintenance segment of the trial lasts 36 weeks, which adds up to 52 weeks of total treatment for those enrolled; beyond that, we'll continue tracking participants for a full year after the 52-week treatment window ends, which lets us assess whether REZPEG might produce remittance effects. Enrollment is proceeding as planned, with roughly 130 clinical investigator sites up and running throughout the US, Canada, Europe and Australia. As Howard said, we expect top line results from the 16-week induction portion of this Phase 2b trial during the first half of 2025, while findings from the study's 36-week maintenance phase should become available near the end of 2025 or in early 2026. Moving now to alopecia areata, a dermal condition confined to hair follicles; with this disease, the immune system of the patient launches an attack on the hair follicle, interfering with its usual capacity to retain and produce hair, which results in hair loss. We see a compelling rationale for REZPEG in this indication, grounded in how T-regs contribute to the pathology underlying the disease. The Phase 2b trial is actively enrolling and intends to bring in 84 patients who have severe to very severe disease, randomly assigned to receive either REZPEG or placebo. Treatment will run for 36 weeks, with observation extending to 60 weeks overall. Mean percent improvement in SALT, or the severity of alopecia tool, at week 36 serves as our primary endpoint, and we look for top line results during the second half of 2025; shifting now to NKTR-0165, our TNFR2 agonist antibody. TNFR2 shows high expression on T-regs, myeloid suppressor cells, regulatory B cells, neuronal cells and others. Within T-regs, TNFR2 agonism has demonstrated the ability to potentiate effector functions, suppressive functions and maintenance of Treg lineage stability, particularly in non-lymphoid tissue compartments. Genetic research indicates that when TNFR2 is missing, the resulting phenotype is autoimmunity along with other conditions resembling FOXP3 loss of function. Conversely, having it present and activating its signaling has been tied to immunoregulatory function and tissue protection effects. Our TNFR2 agonist program rests on many years of Treg expertise that we've accumulated through studying REZPEG. REZPEG, as you're aware, functions as an IL2 receptor pathway agonist that drives JAK STAT signaling in Treg, which is essential for driving Treg proliferation and function within primary and secondary lymphoid organs. TNFR2, by contrast, is the most abundant TNF superfamily member expressed on Tregs and a key activator of NF Kappa B, which additionally governs FOXP3 protein expression and is vital for maintaining Treg function, particularly in the non-lymphoid organs. So, when you look at the REZPEG and TNFR2 agonist programs together, what Nektar has in its pipeline is target rationale covering both lymphoid and non-lymphoid Tregs, and that's among the reasons our excitement around NKTR-0165 is so high. At EULAR back in June of this year, we shared the initial preclinical data on this program, and a number of key takeaways came out of that presentation. Number one, the TNFR2 agonists we identified can signal via the TNFR2 multimeric receptor, a single arm monovalent antibody, which represents a highly novel effect for an agonistic antibody against TNFR2. Number two, our clinical candidate NKTR-0165 showed very high specificity when it comes to binding and signaling through TNFR2 on Tregs, with little to no binding and signaling occurring in conventional T-cells, NK cells or monocytes. Number three, NKTR-0165 as a monotherapy pushed Treg proliferation, upregulation of FOXP3, and other activation markers of primary human Tregs. Number four, confirmation of the PKPD of NKTR-0165 along with efficacy in the KLH DTH model came through a human TNFR2 knock in mouse model. The unique and differentiated profile of the antibodies that were discovered has us very excited, and we are rapidly advancing NKTR-0165 into the clinic, with an IND submission for this program expected in the second half of 2025. Among examples of indications that could be addressed are multiple sclerosis, mucosal immunology conditions such as ulcerative colitis, and even dermal autoimmune diseases such as vitiligo.
Jonathan Zalevsky
executiveSo, given that the TNFR2 agonist antibody specificities we identified function in a single-arm antibody format, we've used that finding to build a pipeline of bispecific molecules containing TNFR2 that combine TNFR2 agonism with other specificities. These new assets harness several mechanisms, yielding novel molecules and novel strategies aimed at autoimmune disease targets. We're eager to share additional detail on this pipeline once development candidates come forward for future clinical entry. On the whole, we've seen rising enthusiasm for a novel, selective TNFR2 agonist such as NKTR-0165, and as we proceed with our IND enabling studies and advance the bispecific pipeline, we'll stay open to the possibility of partnering with companies interested in these areas to map out the optimal path ahead; we have a second preclinical target in immunology, PEG CSF1, known as NKTR-422; that program is a PEG modified hematopoietic colony stimulating factor protein. Today's standard of care — therapies for chronic inflammatory disease — is built to suppress inflammation and isn't optimized for resolving inflammation or restoring tissue homeostasis and tissue function. NKTR-422 aims to stimulate inflammation resolution and tissue repair by targeting the expansion, reprogramming and activation of anti-inflammatory tissue resident macrophages. An agent with those biological properties could establish a new class of anti-inflammatory therapeutics, and that's our goal with NKTR-422. To discover NKTR-422, we screened CSF1 PEG conjugates in vitro and in vivo to identify a CSF1 receptor agonist whose PKPD profile is differentiated relative to the native cytokine; and what we found was that in vivo treatment with NKTR-422 shows significantly reduced target media clearance, sustained target engagement, durable signaling on both the ERK and AKT pathways, proliferation and expansion of tissue resident macrophages with minimal off target effects of monocyte infiltration or production of monocyte derived macrophages. In addition, tissue macrophages induce expression of inflammation resolution and tissue repair markers, including increased IL4 receptor alpha, IL10 receptor alpha cell surface expression, spherocytosis receptor, MerTK regulation and metalloprotease activation. NKTR-422 monotherapy showed efficacy in the mouse CSS colitis model, and combining NKTR-422 with etanercept greatly increased the efficacy of TNF alpha blockade on arthritic PAS swelling after starting treatment at the peak of inflammation in a rat collagen induced arthritis model. As Howard mentioned, data from our early research on this program has been selected for an oral presentation at this year's ACR Convergence Conference. This program has applications across a number of therapeutic indications spanning acute and chronic inflammatory diseases, and we're excited to be presenting this first preclinical data next week. And with that, I'll hand the call over to Mary to discuss NKTR-255. Mary?
Mary Tagliaferri
executiveThanks, JZ. Moving on now to our oncology program built around IL15, since October we've had 3 fresh data disclosures regarding NKTR-255. You can locate every one of those publications and presentations on Nektar's website. To start, the Journal Blood just recently published data from a Stanford study that evaluated NKTR-255 alongside their proprietary CD1922 CAR-T cell for B-cell acute lymphoblastic leukemia. What the results indicate is that when NKTR-255 was added to Stanford's proprietary CAR-T cell therapy, the 12-month relapse free survival rate went up from 38% to 67% relative to Stanford's historical controls. Also worth noting, NKTR-255 improved lymphocyte trafficking to diseased tissue, which gives further support to the mechanism of action. Also, the abstract for the poster we're presenting at ASH was released to the public earlier this week. When the annual conference takes place in December, we'll share the final results from 15 patients enrolled in our Phase 2 placebo-controlled study of NKTR-255 given after approved CD19 CAR-T cell therapies for large B-cell lymphoma. The six-month complete response rate figures we've seen in this trial give us encouragement, since they line up with the findings from the Stanford trial and offer further evidence that NKTR-255 can boost how well CAR-T cell therapy works. And third, the data shared today at SITC strengthens our confidence in NKTR-255's therapeutic promise in a new use — pairing it with checkpoint inhibitors. To give you some context, lymphopenia caused by radiation is a frequent consequence of chemoradiation, and it's associated with poorer overall survival in a number of solid tumors, including lung cancer. Among patients receiving definitive chemoradiation for unresectable locally advanced non-small cell lung cancer, having severe lymphopenia when consolidated durvalumab treatment began proved to be an independent indicator of both shorter progression free survival and shorter overall survival. Interim findings from a Phase 2 trial run by Dr. Stephen Lin <<inaudible>>, which assessed NKTR-255 for rebuilding lymphocyte levels following chemoradiation in locally advanced non-small cell lung cancer patients, were presented by him. When measured against MD Anderson's historical control data, the combination of NKTR-255 and durvalumab produced a statistically significant gain in the eight-week absolute lymphocyte count. The interim findings shared today at SITC as a late-breaking abstract point to a possible clinical upside for NKTR-255 among individuals dealing with locally advanced non-small cell lung cancer. Turning to what comes next, our Phase 1 study alongside AbelZeta keeps moving forward, examining NKTR-255 together with their TILs in advanced non-small cell lung cancer patients who haven't responded to anti PD1 therapy; beyond that, we have a collaboration going with Merck KGaA to study NKTR-255 paired with BAVENCIO in bladder cancer, and the earliest possible PFS readout should arrive either before this year wraps up or during the opening stretch of next year, given that this analysis is event driven. Taking everything into account, the accumulating data makes clear that our IL15 has wide-ranging potential uses. With fresh findings coming in, we keep looking at ways to bring in partners so that work on the NKTR-255 development program can carry forward. On that note, I'll hand things over to Sandra, who will walk us through the financial guidance. Sandra?
Sandra Gardiner
executiveThanks, Mary, and hello everybody this afternoon. We closed out Q3 holding $249 million in cash and investments, and our balance sheet carries no debt at all. Thanks to the $90 million we received from selling our commercial PEG manufacturing facility in Huntsville, Alabama — that's $70 million in cash plus $20 million in equity ownership — our financial footing has gotten even stronger. Our cash runway is now projected to stretch into Q4 of 2026, carrying us across multiple important data milestones, among them top line data from both Phase 2b REZPEG studies; and we're expecting to finish the year with roughly $265 million in cash and investments. Let me quickly walk through the quarter's financials and the revised guidance we're sharing for 2024. Revenue came in at $24.1 million for Q3 of 2024. For the entire year, we're now projecting revenue somewhere between $90 million and $95 million, made up of $60 million to $65 million from non-cash royalties along with $30 million to $35 million from product sales. On our product sales, the gross margin comes out negative. When the Huntsville manufacturing facility sale closes in Q4, we anticipate recording a gain of about $40 million to $45 million. On that gain, we don't anticipate owing any taxes. R&D expense for Q3 of 2024 totaled $35 million; and for the full year, we continue to expect R&D expense in the $120 million to $130 million range, with roughly $10 million of that being non-cash. G&A came to $19 million in Q3 of 2024. For the full year, our G&A expense is now expected to land between $75 million and $80 million, with the non-cash portion rising to approximately $12 million, up from a range of $5 million to $10 million. Finally, non-cash interest expense for 2024 is unchanged and should come in somewhere between $20 million and $25 million. Our net loss for Q3 of 2024 totaled $37 million, which works out to $0.18 basic and diluted loss per share. And as I said before, we're planning to wrap up 2024 with about $265 million in cash and investments and a runway reaching into Q4 of 2026. With all that said, let's go ahead and take questions. Krystal?
Yasmeen Rahimi
analystAfternoon, everyone. Thanks very much for the great updates throughout the whole pipeline. Very useful. So, I suppose I have one question. I believe many investors are waiting eagerly for the AD and AA readouts, and we really appreciated the detail you provided that enrollment is moving along nicely and on schedule to deliver both sets of data. But could you perhaps — is there a chance to put a number on how near we are to getting both studies across the finish line? Do you think? I think that would be quite helpful. And then second, I think the other question asked most frequently concerns the ability to — assuming positive data, particularly from the AD study — how to extrapolate efficacy and biologically experienced patients. And I'm sorry for posing two questions. I'll get back in the queue.
Howard Robin
executiveMary, do you want to handle that question?
Mary Tagliaferri
executiveYes, absolutely. Thank you, Yasmeen, for bringing that up. To begin with your initial point, could we give additional detail regarding enrollment? Let me simply note that this trial kicked off in October 2023, and we've already indicated that topline results are expected during the first half of 2025. What we're prepared to do is update the status on clinicaltrials.gov once enrollment wraps up, so everyone can keep tracking how our study is progressing there. When it comes to efficacy, the Phase 1 trial involved patients who were biologic naive, and we chose to move REZPEG forward into a Phase 2b as well, again in biologically naive patients. That means we'll be able to get a read through of the Phase 1 data. In my view, there isn't a strong understanding right now of what efficacy will look like for biologics in biologically experienced patients; and as additional data emerges from the OX40 studies along with other compounds, we'll gain a clearer picture of the response rate within that population. I believe at this point it's too soon to tell.
Yasmeen Rahimi
analystThank you.
Mary Tagliaferri
executiveThank you, Yasmeen.
Julian Harrison
analystHi there. Thanks for fielding my questions, and congratulations on everything that's been accomplished lately. To start, I'd like to know whether you have a solid idea of when the damages figure might be made public in the case you're currently pursuing against Eli Lilly.
Howard Robin
executiveYeah. Well, as you'd expect, it's really not possible for us to say much about a lawsuit that's still active. What I can share is that mediation is underway. The two sides are in discussions about ways to bring this to a resolution, and we're — Nektar remains completely dedicated to seeing this through, and our belief is that our case is very strong. Beyond that, it's clear that quite a few errors occurred over the course of that clinical trial; so I'm unable to say when a damages figure will be available or when this will be settled. What I can say is that we are vigorously pursuing it, though naturally, since the lawsuit is active, there's only so much I'm able to discuss.
Julian Harrison
analystI see, that makes sense. And if I could squeeze in one more question. Regarding your Phase 2b atopic dermatitis trial, could you remind us what the protocol says about how corticosteroids are used?
Howard Robin
executiveMary, would you like to take that one?
Mary Tagliaferri
executiveRight. So this isn't a trial involving combination therapy. Before entering the study, patients need to wash out their topical corticosteroid use. After that, they aren't allowed to use topical corticosteroids, and should they do so following the initial 2 weeks of treatment, that would count as rescue medication use, and treatment would be stopped for those patients.
Julian Harrison
analystUnderstood. Therefore, every rescue counts as a study discontinuation?
Mary Tagliaferri
executiveYes, that's right. One element of our trial, I believe, gave patients an incentive to remain in the trial and follow the rules prohibiting any use of topical corticosteroids: following the 16-week induction period, provided patients have complied with the protocol, they may have the opportunity to undergo re-randomization into the maintenance period. And naturally, should they not be responders, they will enter an escape arm and get the highest dose of REZPEG. So especially for patients who lack great access to biologics, in Europe, where we plan to enroll approximately 65% of the patients, I think we will observe strong adherence to the protocol.
Julian Harrison
analystAll right. That's really useful. Thanks so much.
Analyst
analystHi there, Chong here, calling in for Jay. I appreciate you fielding this question, and congratulations on the progress. I wanted to ask specifically about the REZPEG AD trial. Given that patient enrollment has been going on for a while at this point, could you shed some light on what the baseline characteristics of those patients look like — for instance, the baseline EC score? And beyond that, if you're able to break down how many participants came from sites in the US compared with sites outside the US, that would be extremely helpful. Thank you.
Mary Tagliaferri
executiveYes. Hello, Mary speaking. The design here is fully blinded, and we have taken great care in crafting the protocols and the plans so that data gets captured, and captured in a way that is both accurate and timely, and so that our data is cleaned and the blinding of this study is preserved. Speaking for myself, I have not been reviewing that pooled information under blinded conditions, and we commit to giving you both very transparent baseline characteristic traits and very transparent top line data covering three distinct doses against placebo.
Analyst
analystUnderstood. Thanks.
Jessica Fye
analystHey everyone, good afternoon, and thanks for taking my questions. So, first one, the data at EADV on serum proteomic biomarkers in AD. I think it was mentioned that REZPEG lowered expression of serum proteins that are known to be elevated in AD, and I was wondering whether those expression levels remain reduced even after REZPEG therapy is stopped. Just sort of trying to understand the phenomenon you saw where patients had sustained benefit even after stopping REZPEG in the Phase 1b.
Jonathan Zalevsky
executiveYeah. Hey Jess, this is JZ. That's a great question. Unfortunately, though, the last time point that was collected in that study was week 12 at the end of induction; so, we don't have proteomic results beyond into the drug free follow up; however, in the Phase 2 we are collecting samples all through the maintenance period and also after the one year of treatment, in the one year follow up; so, we'll be able to answer your question very directly in that study, but not in the Phase 1b where collection stops at week 12.
Jessica Fye
analystAll right. And please excuse me if I simply missed this, but regarding the change in the alopecia timeline — I believe it was previously the first half, after that mid '25, and currently it's the back half of '25 — is that essentially a hold-up in getting sites operational? Is it screen failure or another issue? What exactly is driving that change in timing?
Jonathan Zalevsky
executiveYeah; so that trial started in — Mary, go ahead.
Mary Tagliaferri
executiveOkay, this is Mary Tagliaferri speaking. So, the atopic dermatitis trial kicked off in October 2023, as you're aware. Then roughly 5 months afterward, we launched the alopecia areata study; patients in that one get followed across 36 weeks of treatment. So I wouldn't say we're particularly far from our projections. I'd say we're quite near what we forecast when the study got underway. Enrollment is happening in Canada, the United States, and Europe; it's a fact that with any immunology trial these days, and given the globalization process in Europe, getting European sites up and running takes more time than it does in the US, so you definitely begin enrolling earlier in the United States and Canada. Still, we're on the timelines we projected, and the data will come in the second half of 2025.
Jessica Fye
analystThank you.
Andy Hsieh
analystHey, thanks for letting us ask questions. I wanted to ask about the SITC poster that was shown today. First, you examined NK cell proliferation. I'm curious whether you also looked at any other cell populations that might be relevant. That's the first part. Second, regarding the control arm, Mary, I believe you mentioned that these patients were essentially taken from MD Anderson, so basically the same institution. I'd like to know whether the lymphocyte count pattern resembles what has been seen in some of the Pacific studies conducted with AstraZeneca. I'm just wondering about how consistent that trend is in the control arm. Thank you.
Mary Tagliaferri
executiveSure. Hi, Andy. This is Mary. As far as the historical control arms go, all of these patients were treated at MD Anderson. Thirty-nine of them predated the approval of durvalumab. So they received chemoradiation only. Then there were 120 patients who got CRT plus durva. The ALC counts across these patient populations are fairly similar. What Dr. Lin presented today was that at cycle one, day eight, the median increase in ALC was 2.35 fold higher. At cycle two, day eight, it was 3.6 fold higher. These results were statistically significant versus his controls. What amazes him is how long the lymphopenia persists in these patient populations, and that it's striking that this effect continues for 12 months after radiation therapy is completed. I'm not sure, Andy, whether you're familiar with the literature, but Steven Lin included in the background information his data from the study he conducted with, again, a comparable patient population. There has also been a second study completed at Johns Hopkins, and it's by an author named Fredes <>. What he demonstrated was that he used a slightly different absolute lymphocyte count than Stephen Lin. Stephen Lin used 0.23 times 10 to the 9th liters for lymphocytes. At the Johns Hopkins center, they used 0.5. They showed that the median PFS for those patients with severe lymphopenia — and this is on the Pacific regimen on durvalumab — was only 217 days, which is about seven months, versus 570 days for those patients who didn't have it. And when you look at what the median PFS was in the Pacific trial for patients on placebo, it was 5.6 months. So what Stephen Lin's point is, when you look at these data, it's astonishing that patients with severe radiation induced lymphopenia at various thresholds really don't do well and seem to have very, very little benefit from durvalumab. Therefore, he strongly believes that combining NKTR-255 with durvalumab in this setting would be a very powerful mechanism to improve the PFS and overall survival of these patients who aren't deriving benefit today of a checkpoint inhibitor.
Jonathan Zalevsky
executiveRegarding your initial inquiry, Andy, I can address that. Today's presentation covered NK cell impacts, including effects on proliferation and alterations to cell surface proteins tied to NK cell activity, along with certain phenotypic functions that were displayed—these being among the drug's targets. However, within the trial, there is considerably more phenotypic examination, plus evaluation of T-cell populations and then measurement of the general percentage of cells among patients who bounced back from lymphopenia. Examining the memory cell reservoirs, and additionally assessing overall health—one of the fundamental hypotheses, as Mary also brought up, concerns the cells themselves, since in patients suffering from lymphopenia, those cells are absent. Lymphocytes are likely also absent from the targeted tumor. So we're also examining how specific populations recover. All of these represent essential goals that are emerging within the study.
Arthur He
analystHello there, and good afternoon to all of you. I've got one brief item I wanted to ask about, and it concerns how the AD study was designed. Specifically, once that 36-week maintenance phase wraps up, will patients be given the chance to keep getting the treatment without interruption through the follow-up?
Mary Tagliaferri
executiveHi, Mary here.
Jonathan Zalevsky
executiveHey, Arthur.
Mary Tagliaferri
executiveI am sorry. Go ahead, JZ.
Jonathan Zalevsky
executiveRight. What I was about to add, Arthur, is that in this particular study, patients go through 52 weeks of treatment altogether — that includes both the 16-week induction phase and the maintenance phase — and after that, they're monitored for 52 weeks without any additional treatment. So one goal we have is to treat for a year, then evaluate the remission effect following a year of therapy.
Arthur He
analystGot it. That tells me we'll be able to obtain the information on the off-treatment control coming out of this trial.
Jonathan Zalevsky
executiveYes. To give you an instance, assuming the program keeps going and, let's say, advances into later-stage trials such as Phase 3, in time this Phase 2 trial will end up with results covering the one year of treatment plus the one year of off-treatment follow up; you've got that exactly right.
Arthur He
analystAll right, understood. Thanks for the details.
Howard Robin
executiveSo, thanks to all of you for being with us on this call. Our attention continues to be directed toward moving our I&I pipeline forward, and there is a lot of excitement on our part regarding what every one of our distinctive programs could achieve. My appreciation goes out to every member of our workforce for the effort and care they bring, and I also want to express gratitude to those who have invested with us for standing by us. We are eager to keep you informed about how our efforts are progressing. So keep watching. Many thanks.
Operator
operatorThanks a lot. That brings us to the end of today's conference call. We appreciate everyone joining us. You're free to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.